Herpes Labialis (Oral Herpes) - Pipeline Review, H2 2017

Date: November 14, 2017
Pages: 48
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: HB57E55CF4DEN
Leaflet:

Download PDF Leaflet

Herpes Labialis (Oral Herpes) - Pipeline Review, H2 2017
Herpes Labialis (Oral Herpes) - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Herpes Labialis (Oral Herpes) - Pipeline Review, H2 2017, provides an overview of the Herpes Labialis (Oral Herpes) (Infectious Disease) pipeline landscape.

Oral herpes is an infection of the lips, mouth, or gums due to the herpes simplex virus. Oral herpes is also called herpes labialis. Symptoms include sore throat, fever, swollen glands and painful swallowing. Treatment includes antiviral medications.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Herpes Labialis (Oral Herpes) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Herpes Labialis (Oral Herpes) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Herpes Labialis (Oral Herpes) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Herpes Labialis (Oral Herpes) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Preclinical and Discovery stages are 1, 4, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Herpes Labialis (Oral Herpes) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Herpes Labialis (Oral Herpes) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Herpes Labialis (Oral Herpes) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Herpes Labialis (Oral Herpes) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Herpes Labialis (Oral Herpes) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Herpes Labialis (Oral Herpes) (Infectious Disease)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Herpes Labialis (Oral Herpes) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Herpes Labialis (Oral Herpes) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Herpes Labialis (Oral Herpes) - Overview
Herpes Labialis (Oral Herpes) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Herpes Labialis (Oral Herpes) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Herpes Labialis (Oral Herpes) - Companies Involved in Therapeutics Development
AiCuris GmbH & Co KG
Beech Tree Labs Inc
NanoViricides Inc
Onxeo SA
Shulov Innovative Science Ltd
Vironova AB
Herpes Labialis (Oral Herpes) - Drug Profiles
acyclovir - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Aspidasept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
B-220 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BTL-TMLHSV - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
herpes simplex virus [type 1, 2] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pritelivir - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Cold Sores - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
squaric acid dibutyl ester - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZEP-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Herpes Labialis (Oral Herpes) - Dormant Projects
Herpes Labialis (Oral Herpes) - Discontinued Products
Herpes Labialis (Oral Herpes) - Product Development Milestones
Featured News & Press Releases
Aug 23, 2017: AiCuris Announces Final Patient Treated in Clinical Phase 2 Trial with Topical Pritelivir for the Treatment of recurrent Labial Herpes
May 24, 2017: Cold Sore Treatment Developed by Squarex Shown Effective by Immunotherapy Study
Dec 01, 2016: AiCuris Announces Start of LipP 1: First Subject Enrolled in the Clinical Phase 2 Trial with Topical Pritelivir for the Treatment of recurrent Labial Herpes
Feb 16, 2016: Cipher Pharmaceuticals announces Sitavig accepted for review by Health Canada
Jul 21, 2014: BioAlliance Pharma announces the launch of Sitavig in the United States by its partner Innocutis and the granting of a new U.S. Sitavig patent
Jul 10, 2013: BioAlliance Pharma expands and strengthens its industrial property assets with two patent grants
May 27, 2013: BioAlliance Pharma Presents Results Of Sitavig At 10th EADV Symposium
Apr 15, 2013: BioAlliance Pharma's Sitavig Receives US Marketing Authorization For Treatment Of Herpes Labialis
Apr 04, 2013: Beech Tree Labs Successfully Completes IND Phase I/IIa Oral Herpes Clinical Trial
Jul 26, 2012: BioAlliance Pharma Receives US Patent Covering Sitavig
May 29, 2012: BioAlliance Announces Receivability Of Sitavig US Registration Dossier
Oct 05, 2011: BioAlliance Submits Sitavir European Registration Dossier Through European Decentralized Procedure
Feb 07, 2011: BioAlliance Pharma Presents Results Of International Survey Performed With Nielsen In Patients Suffering From Herpes Labialis
Nov 17, 2010: BioAlliance Pharma Presents Pharmacokinetic Results Of Sitavir At AAPS Annual Meeting
Nov 05, 2010: AiCuris To Present Preclinical And Phase I Data Of Anti-HSV Drug AIC316 At Antivirals Congress
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Herpes Labialis (Oral Herpes), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Herpes Labialis (Oral Herpes) - Pipeline by AiCuris GmbH & Co KG, H2 2017
Herpes Labialis (Oral Herpes) - Pipeline by Beech Tree Labs Inc, H2 2017
Herpes Labialis (Oral Herpes) - Pipeline by NanoViricides Inc, H2 2017
Herpes Labialis (Oral Herpes) - Pipeline by Onxeo SA, H2 2017
Herpes Labialis (Oral Herpes) - Pipeline by Shulov Innovative Science Ltd, H2 2017
Herpes Labialis (Oral Herpes) - Pipeline by Vironova AB, H2 2017
Herpes Labialis (Oral Herpes) - Dormant Projects, H2 2017
Herpes Labialis (Oral Herpes) - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Herpes Labialis (Oral Herpes), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Targets, H2 2017
Number of Products by Stage and Targets, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

COMPANIES MENTIONED

AiCuris GmbH & Co KG
Beech Tree Labs Inc
NanoViricides Inc
Onxeo SA
Shulov Innovative Science Ltd
Vironova AB
Skip to top


Genital Herpes - Pipeline Review, H2 2017 US$ 2,000.00 Aug, 2017 · 97 pages

Ask Your Question

Herpes Labialis (Oral Herpes) - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: